首站-论文投稿智能助手
典型文献
Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment
文献摘要:
The ubiquitin-proteasome system(UPS)is essential for maintaining cell homeostasis by orchestrating the protein degradation,but is impaired in various diseases,including cancers.Several proteasome inhibitors,such as bortezomib,are currently used in cancer treatment,but associated toxicity limits their widespread application.Recently metal complex-based drugs have attracted great attention in tumor therapy;however,their application is hindered by low water-solubility and poor absorbency.Herein,we synthesized a new type of gold(Ⅰ)complex named Na-AuPT,and further characterized its anticancer activity.Na-AuPT is highly water-soluble(6 mg/mL),and it was able to potently inhibit growth of a panel of 11 cancer cell lines(A549,SMMC7721,H460,HepG2,BEL7402,LNCap,PC3,MGC-803,SGC-7901,U266,and K562).In A549 and SMMC7721 cells,Na-AuPT(in a range of 2.5-20μM)inhibited the UPS function in a dose-dependent fashion by targeting and inhibiting both 20 S proteasomal proteolytic peptidases and 19 S proteasomal deubiquitinases.Furthermore,Na-AuPT induced caspase-dependent apoptosis in A549 and SMMC7721 cells,which was prevented by the metal chelator EDTA.Administration of Na-AuPT(40 mg·kg-1·d-1,ip)in nude mice bearing A549 or SMMC7721 xenografts significantly inhibited the tumor growth in vivo,accompanied by increased levels of total ubiquitinated proteins,cleaved caspase 3 and Bax protein in tumor tissue.Moreover,Na-AuPT induced cell death of primary mononuclear cells from 5 patients with acute myeloid leukemia ex vivo with an average IC50 value of 2.46 μM.We conclude that Na-AuPT is a novel metal-based proteasome inhibitor that may hold great potential for cancer therapy.
文献关键词:
作者姓名:
Da-cai Xu;Li Yang;Pei-quan Zhang;Ding Yan;Qian Xue;Qing-tian Huang;Xiao-fen Li;Ya-li Hao;Dao-lin Tang;Q.Ping Dou;Xin Chen;Jin-bao Liu
作者机构:
Affliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;The Department of Physiology,School of Basic Medical Sciences,Guizhou Medical University,Guiyang 550003,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
引用格式:
[1]Da-cai Xu;Li Yang;Pei-quan Zhang;Ding Yan;Qian Xue;Qing-tian Huang;Xiao-fen Li;Ya-li Hao;Dao-lin Tang;Q.Ping Dou;Xin Chen;Jin-bao Liu-.Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment)[J].中国药理学报(英文版),2022(08):2128-2138
A类:
AuPT,absorbency,deubiquitinases
B类:
Pharmacological,characterization,novel,metal,proteasome,Na,treatment,system,UPS,essential,maintaining,homeostasis,by,orchestrating,degradation,but,impaired,various,diseases,including,cancers,Several,inhibitors,such,bortezomib,are,currently,used,associated,toxicity,limits,their,widespread,application,Recently,complex,drugs,have,attracted,great,attention,tumor,therapy,however,hindered,low,water,solubility,poor,Herein,synthesized,new,type,gold,named,further,characterized,anticancer,activity,highly,soluble,was,able,potently,growth,panel,lines,A549,SMMC7721,H460,HepG2,BEL7402,LNCap,PC3,MGC,SGC,U266,K562,In,cells,range,inhibited,function,dose,dependent,fashion,targeting,inhibiting,both,proteasomal,proteolytic,peptidases,Furthermore,induced,caspase,apoptosis,which,prevented,chelator,EDTA,Administration,ip,nude,mice,bearing,xenografts,significantly,vivo,accompanied,increased,levels,total,ubiquitinated,proteins,cleaved,Bax,tissue,Moreover,death,primary,mononuclear,from,patients,acute,myeloid,leukemia,average,IC50,value,We,conclude,that,may,hold,potential
AB值:
0.57897
相似文献
Drug repurposing for cancer treatment through global propagation with a greedy algorithm in a multilayer network
Xi Cheng;Wensi Zhao;Mengdi Zhu;Bo Wang;Xuege Wang;Xiaoyun Yang;Yuqi Huang;Minjia Tan;Jing Li-Department of Bioinformatics and Biostatistics,School of Life Sciences and Biotechnology,Shanghai Jiao Tong University,Shanghai 200240,China;The Chemical Proteomics Center and State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Key Laboratory of Tissue Microenvironment and Tumor,Shanghai Institute of Nutrition and Health,Shanghai Institutes for Biological Sciences,University of Chinese Academy of Sciences,Chinese Academy of Sciences(CAS),Shanghai 200031,China
CUL4B facilitates HBV replication by promoting HBx stabilization
Haixia Shan;Bo Wang;Xiaodong Zhang;Hui Song;Xi Li;Yongxin Zou;Baichun Jiang;Huili Hu;Hao Dou;Changshun Shao;Lifen Gao;Chunhong Ma;Xiaoyun Yang;Xiaohong Liang;Yaoqin Gong-Key Laboratory for Experimental Teratology of the Ministry of Education,Key Laboratory of Infection and Immunity of Shandong Province and Department of Immunology,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Department of Laboratory Diagnosis,Cangzhou Combination of Traditional Chinese and Western Medicine Hospital of Hebei Province,Cangzhou 061000,China;Division of Gastroenterology and Hepatology,Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai Institute of Digestive Disease,Shanghai 200120,China;Ministry of Education Key Laboratory of Experimental Teratology and Institute of Molecular Medicine and Genetics,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Collaborative Innovation Center of Technology and Equipment for Biological Diagnosis and Therapy in Universities of Shandong,Jinan 250012,China;Department of Gastroenterology,Qilu Hospital,Shandong University,Jinan 250012,China
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
Tingting Feng;Jing Wang;Kai Cheng;Qiqi Lu;Ru Zhao;Shiguan Wang;Qingyun Zhang;Luna Ge;Jihong Pan;Guanhua Song;Lin Wang-Department of Pathology,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Department of Pathology,The Fourth People's Hospital of Jinan,Jinan 250031,China;Department of PET-CT,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250002,China;The Second Hospital,Cheeloo College of Medicine,Shandong University Medical School,Jinan 250012,China;Biomedical Sciences College&Shandong Medicinal Biotechnology Centre,Key Lab for Biotech-Drugs of National Health Commission,Key Lab for Rare&Uncommon Diseases of Shandong Province,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Biochemistry and Molecular Biology,Shandong University School of Basic Medical Sciences,Jinan 250012,China;Institute of Basic Medicine,Shandong Academy of Medical Sciences,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Oncology,The First Affiliated Hospital of Shandong First Medical University,Jinan 250014,China
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
Paired box 5 increases the chemosensitivity of esophageal squamous cell cancer cells by promoting p53 signaling activity
Zhang Weiwei;Yan Wenji;Qian Niansong;Han Quanli;Zhang Weitao;Dai Guanghai-Chinese People’s Liberation Army Medical School, Beijing 100853, China;Department of the Third Health Care, The Second Medical Center, Chinese People’s Liberation Army General Hospital, Beijing 100853, China;Department of Oncology, The First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing 100853, China;Department of Oncology, The Hainan Medical Center, Chinese People’s Liberation Army General Hospital, Sanya 572022, China;Cancer Center, Beijing Tongren Hospital Affiliated to Capital Medical University, Economic and Technological Development Zone, Beijing 100176, China
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou;Libin Zou;Hangyu Liao;Junqi Luo;Taowei Yang;Jun Wu;Wenbin Chen;Kaihui Wu;Shengren Cen;Daojun Lv;Fangpeng Shu;Yu Yang;Chun Li;Bingkun Li;Xiangming Mao-Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Second Department of Hepatobiliary Surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Department of Urology,Minimally Invasive Surgery Center,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Urology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Urology,Peking University Shenzhen Hospital,Shenzhen 518036,China;Nursing Department,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models
Ming Ji;Dongjie Wang;Songwen Lin;Chunyang Wang;Ling Li;Zhihui Zhang;Jing Jin;Deyu Wu;Yi Dong;Heng Xu;Duo Lu;Xiaoguang Chen-State Key Laboratory of Bioactive Substances and Functions of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。